Alderley Park
Suite 24G13 - Block 24 Congleton Road
Nether Alderley SK10 4TG
United Kingdom
44 1625 315 090
https://theracryf.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 10
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Huw Jones BSc, Ph.D. | CEO & Executive Director | 304,73k | N/D | 1959 |
Mr. Toni Haenninen | CFO & Director | N/D | N/D | 1977 |
Dr. Helen Kuhlman Ph.D. | Chief Business Officer | N/D | N/D | N/D |
Dr. Glen Clack FFPM, M.D. | Chief Medical Officer | N/D | N/D | N/D |
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders. The company's lead product is SFX-01 that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma and Phase I clinical trials for the treatment of neurodevelopmental disorders, as well as in preclinical stage for the treatment of rhabdomyosarcoma. In addition, it engages in the development of orexin 1 antagonist, which is in late preclinical stage targeting addictive behaviors; orexin 1 antagonist that is in late preclinical stage for the treatment of anxiety; and molecule DAT inhibitor, which is in late preclinical stage targeting fatigue and narcolepsy. The company has a partnership with Stalicla to collaborate on a clinical program in autism spectrum disorder. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.
L'ISS Governance QualityScore di Theracryf Plc al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.